doripenem
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia
Conditions
Pneumonia
Trial Timeline
May 1, 2004 → Oct 1, 2006
NCT ID
NCT00211003About doripenem
doripenem is a phase 3 stage product being developed by Johnson & Johnson for Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00211003. Target conditions include Pneumonia.
What happened to similar drugs?
20 of 20 similar drugs in Pneumonia were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00986102 | Approved | Completed |
| NCT00211016 | Phase 3 | Completed |
| NCT00211003 | Phase 3 | Completed |
| NCT00210990 | Phase 3 | Completed |
| NCT00210938 | Phase 3 | Completed |
| NCT00229060 | Phase 3 | Completed |
Competing Products
20 competing products in Pneumonia